Message #12 From:
NewsBot Date: December 15, 2005 03:21:00 AM
PBME News Pacific Biometrics Highlighted In KonLin Letter; Pacific Biometrics Listed As 'Featured Stock Of The Month' In December 2005 Issue Of The KonLin Letter
SEATTLE--(BUSINESS WIRE)--Dec. 15, 2005--Pacific Biometrics (OTCBB:PBME), a provider of specialized central laboratory and contract research services to pharmaceutical and diagnostic manufacturers conducting human clinical trial research, has been favorably reviewed as "Featured Stock Of The Month" in the KonLin Letter, a monthly subscription-based financial letter published by Kon-Lin Research & Analysis Corp. of Rocky Point, New York.
The KonLin Letter is a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements. Pacific Biometrics was not involved in preparing the report published in the KonLin Letter and assumes no responsibility for the accuracy or content of the information contained in the report. Interested parties are asked to visit www.konlin.com for further information.
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including to but not limited to our strategic planning and business development plans, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2005 and our Form 10-QSB for the quarter ended September 30, 2005).
